Your search returned 6 results.

Results
	1.	Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in Stable Patients With Schizophrenia. [electronic resource] by Dammerman, Ryan Kim, Sonnie Adera, Mathews Schwarz, Alex Producer: 20190613 In: Clinical pharmacology in drug development vol. 7 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	A Phase 1, Open-Label, Single Dose Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant. [electronic resource] by Dammerman, Ryan Kim, Sonnie Adera, Mathews Schwarz, Alex Publication details: Psychopharmacology bulletin 09 2017 In: Psychopharmacology bulletin vol. 47 Availability: No items available. Save to lists Add to cart (remove)
	3.	A Phase-1, 6-Month Open-Label, Dose-Ranging Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant. [electronic resource] by Dammerman, Ryan Kim, Sonnie Adera, Mathews Schwarz, Alex Publication details: Psychopharmacology bulletin 09 2017 In: Psychopharmacology bulletin vol. 47 Availability: No items available. Save to lists Add to cart (remove)
	4.	Pharmacokinetics and Safety of Migalastat HCl and Effects on Agalsidase Activity in Healthy Volunteers. [electronic resource] by Johnson, Franklin K Mudd, Paul N Bragat, Alexander Adera, Mathews Boudes, Pol Producer: 20160429 In: Clinical pharmacology in drug development vol. 2 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. [electronic resource] by McClung, Michael Recker, Robert Miller, Paul Fiske, Darrell Minkoff, Jerome Kriegman, Audrey Zhou, Wenchun Adera, Mathews Davis, Jenny Producer: 20070914 In: Bone vol. 41 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase. [electronic resource] by Warnock, David G Bichet, Daniel G Holida, Myrl Goker-Alpan, Ozlem Nicholls, Kathy Thomas, Mark Eyskens, Francois Shankar, Suma Adera, Mathews Sitaraman, Sheela Khanna, Richie Flanagan, John J Wustman, Brandon A Barth, Jay Barlow, Carrolee Valenzano, Kenneth J Lockhart, David J Boudes, Pol Johnson, Franklin K Producer: 20160508 In: PloS one vol. 10 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)